Related Experiment Video
Updated: Jun 18, 2026
Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction
Published on: October 13, 2017
Use of a chitosan-based hemostatic dressing in dacryocystorhinostomy
Roger A Dailey1, Mauricio R Chavez, Dongseok Choi
1Oculofacial Plastic and Reconstructive Surgery, Casey Eye Institute, Oregon Health Sciences University, Portland, Oregon 97239, USA.
Insights
Chitosan-based hemostatic dressing (CBHD) proved effective for dacryocystorhinostomy (DCR) surgery, significantly reducing postoperative bleeding compared to collagen absorbable hemostat (CAH). This study highlights CBHD as a safe and promising alternative for DCR procedures.
Area of Science:
- Ophthalmology
- Surgical Innovation
- Biomaterials
Background:
- Dacryocystorhinostomy (DCR) surgery aims to restore lacrimal drainage.
- Effective hemostasis is crucial during DCR to minimize complications.
- Comparing hemostatic agents aids in optimizing surgical outcomes.
Purpose of the Study:
- To evaluate chitosan-based hemostatic dressing (CBHD) as an adjunct for hemostasis in DCR and conjunctival DCR (CDCR) surgery.
- To compare the effectiveness of CBHD against collagen absorbable hemostat (CAH).
Main Methods:
- Retrospective, comparative case series involving 61 patients undergoing DCR or CDCR.
- 35 procedures utilized CBHD, while 35 procedures used CAH.
- Outcomes measured included postoperative bleeding and the need for nasal packing.
Main Results:
- Postoperative bleeding occurred in 2 cases with CBHD versus 12 cases with CAH.
- CBHD demonstrated a lower incidence of bleeding complications.
Conclusions:
- Chitosan-based hemostatic dressing (CBHD) is effective and safe for DCR and CDCR surgeries.
- CBHD presents a promising alternative to collagen absorbable hemostat (CAH) for improving hemostasis.
Purpose:
To evaluate the use of a chitosan-based hemostatic dressing (CBHD) (ChitoFlex, HemCon Medical Technologies Inc., Portland, OR, U.S.A.) as an effective adjunct for hemostasis in dacryocystorhinostomy surgery and compare its effectiveness to collagen absorbable hemostat (CAH) (Insat, Johnson & Johnson Gateway, New Brunswick, NJ, U.S.A.).
Methods:
Retrospective, comparative case series. Thirty-five external or endoscopic dacryocystorhinostomy (DCR) and conjuctival dacryocystorhinostomy (CDCR) procedures were performed on 26 patients using the CBHD from May through October 2007. Thirty-five external or endoscopic DCR or CDCR procedures were performed on 27 patients using CAH from February through May 2007. Collection of patient data in the group treated with CBHD included the types of cases performed, surgical outcome, complications, adverse reactions, and telephone follow-up survey of symptomatic results. Collection of patient data in the group treated with CAH primarily focused on the types of cases performed and postoperative bleeding. The main outcome measures were postoperative bleeding and need for anterior nasal packing.
Results:
Postoperative bleeding occurred in 2 cases in the group treated with CBHD and in 12 cases in the CAH group.
Conclusions:
The study demonstrates the effectiveness and safety of CBHD as a hemostatic agent in DCR and CDCR and as a promising alternative to CAH.
